NewAmsterdam Pharma Company N.V.

NAMS

Equity

ISIN NL00150012L7 / Valor 123483043

NASDAQ (2026-01-21)

USD 33.94+4.72%

NewAmsterdam Pharma Company N.V.
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm focused on the development of innovative therapies for cardiovascular diseases. The company's lead investigational candidate, obicetrapib, is a selective inhibitor targeting the Cholesteryl Ester Transfer Protein (CETP). Clinical trials have demonstrated that obicetrapib significantly reduces low-density lipoprotein cholesterol (LDL-C) while increasing high-density lipoprotein cholesterol (HDL-C), potentially transforming the ratio of good versus bad cholesterol in the body. This mechanism of action aims to lower the risk of adverse cardiovascular outcomes, as evidenced by previous CETP inhibitors that have shown clinical benefits in large-scale trials. Obicetrapib is distinguished by its improved selectivity, potency, and favorable safety and tolerability profile compared to earlier CETP inhibitors.

Summarized from source with an LLMView SourceSector: Finance

Latest Results ():

Summarized from source with an LLMView Source

Key figures

43.2%1Y

217%3Y

%5Y

Performance

57.5%1Y

68.4%3Y

70.6%5Y

Volatility